Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard McLeod

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Pharmacogenomics|December 26, 2006
Graying anatomy? Toward molecular tumor characterizationHoward McLeod
The Journal of Rheumatology|May 5, 2010
Race and methotrexate pharmacogenetics in rheumatoid arthritisPrabha Ranganathan, Howard McLeod
Pharmacogenomics|April 21, 2012
Use of CYP2D6 genotyping in practice: tamoxifen dose adjustmentChristine M Walko, Howard McLeod
Nature Clinical Practice. Oncology|January 29, 2009
Pharmacogenomic progress in individualized dosing of key drugs for cancer patientsChristine M Walko, Howard McLeod
Oncology (Williston Park, N.Y.)|February 3, 2005
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an updateWilliam Read, Howard McLeod, Ramaswamy Govindan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2004
The pharmacogenetics of antiretroviral therapy: a review of studies to dateErin Quirk, Howard McLeod, William Powderly
Clinical Colorectal Cancer|February 11, 2009
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancerShriya Bhushan, Howard McLeod, Christine M Walko
Bulletin of the World Health Organization|November 16, 2011
Can pharmacogenomics improve malaria drug policy?Mary W Roederer, Howard McLeod, Jonathan J Juliano
Transactions of the American Clinical and Climatological Association|August 11, 2010
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogeneticsRichard M Goldberg, Daniel J Sargent, Howard McLeod
Current Oncology Reports|March 21, 2013
Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Morgan Trammel, Mary Roederer, Jai Patel, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Pharmacogenomics|December 26, 2006
Graying anatomy? Toward molecular tumor characterizationHoward McLeod
The Journal of Rheumatology|May 5, 2010
Race and methotrexate pharmacogenetics in rheumatoid arthritisPrabha Ranganathan, Howard McLeod
Pharmacogenomics|April 21, 2012
Use of CYP2D6 genotyping in practice: tamoxifen dose adjustmentChristine M Walko, Howard McLeod
Nature Clinical Practice. Oncology|January 29, 2009
Pharmacogenomic progress in individualized dosing of key drugs for cancer patientsChristine M Walko, Howard McLeod
Oncology (Williston Park, N.Y.)|February 3, 2005
Irinotecan and carboplatin in metastatic or recurrent NSCLC: an updateWilliam Read, Howard McLeod, Ramaswamy Govindan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2004
The pharmacogenetics of antiretroviral therapy: a review of studies to dateErin Quirk, Howard McLeod, William Powderly
Clinical Colorectal Cancer|February 11, 2009
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancerShriya Bhushan, Howard McLeod, Christine M Walko
Bulletin of the World Health Organization|November 16, 2011
Can pharmacogenomics improve malaria drug policy?Mary W Roederer, Howard McLeod, Jonathan J Juliano
Transactions of the American Clinical and Climatological Association|August 11, 2010
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogeneticsRichard M Goldberg, Daniel J Sargent, Howard McLeod
Current Oncology Reports|March 21, 2013
Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?Morgan Trammel, Mary Roederer, Jai Patel, et al.
Pageof 5